Background. Measuring the serum and alveolar procalcitonin level as inflammatory marker in the diagnosis of ventilator-associated pneumonia (VAP) has been taken into account. In this study, serum and alveolar procalcitonin levels in patients with suspected VAP and patients with confirmed VAP were compared.
INTRODUCTION
Ventilator-associated pneumonia (VAP) is one of the most common causes of death from infectious diseases in ICU [1] . The prevalence of this infection varies from 10 to 20%, depending on definition of pneumonia, type of ICU, target population and level of exposure to antibiotics such that 70% of patients with acute respiratory distress syndrome will suffer from pneumonia during their stay in ICU [2, 3] . Iran is one of the countries with highest incidence of nosocomial pneumonia in ICU patients with mechanical ventilation [4] . In some reports, the mortality was two times more than in patients without VAP and its crude mortality rate was found to be more than 50% [5] . This disease is associated with prolonged mechanical ventilation and hospitalization, excessive use of human resources, high treatment costs and high mortality rate.
Procalcitonin is a peptide precursor of calcitonin made of 116 amino acids, which is produced in several body organs in response to inflammation or infection [6] . Its value increases 3 to 6 hours after the initial stimulation and its higher value is associated with worse prognosis [7] . This polypeptide is considered as the primary marker for the diagnosis of infections. Increase in its value can prove the existence of infection, particularly bacterial infection associated with systemic response of the body. Moreover, procalcitonin has been measured and evaluated as predictive factor of infection in various diseases such as cirrhosis of liver and pneumonia [8, 9] . In recent years, special attention has been paid to the role of increased serum procalcitonin level in lung injury and its infections. Alveolar procalcitonin has also been evaluated in patients with VAP lately and its value in patients with confirmed VAP was microbiologically different from patients with suspected VAP [10] . In addition, serum procalcitonin level has been considered as a mortality index. Despite the high incidence of VAP, its diagnosis presents a challenge to physicians because there are many similar conditions in ICU patients such as acute respiratory distress syndrome, sepsis, heart failure and pulmonary atelectasis that reveal similar symptoms. Unfortunately, there is no reliable gold standard for diagnosis of VAP [11] . However, evaluation of serum and alveolar procalcitonin is used in some cases to diagnose VAP. Due to specificity of alveolar procalcitonin for early diagnosis of ventilator-associated pneumonia, this study was also dedicated to usability and comparison of serum and alveolar procalcitonin level in patients with suspected VAP and patients with confirmed VAP.
MATERIALS AND METHODS

STUDY SUBJECTS
In this cross-sectional study, the target population included 120 intubated ICU patients (48 hours after intubation) in Ayatollah Rohani Hospital in Babol, Northern Iran, from October 2014 to April 2015 using census method. The exclusion criteria were hypoxia, coagulation disorders, pleural and pulmonary adhesions, empyema and skin infection in insertion site of the tube. Diagnosis of ventilator-associated pneumonia was done according to clinical examination and BAL cultures.
All patients with suspected VAP were examined daily and bronchoalveolar lavage was performed for 50 patients with clinical pulmonary infection score ≥ 6 and quantitative culture and serum and alveolar procalcitonin evaluation was done using (CPIS( Clinical Pulmonary Infection Score [12] . Alveolar procalcitonin was measured using enzymelinked fluorescence assay (ProCa-S test PCT, Brahms Diagnostics, Norcross, Georgia, USA) and serum procalcitonin was measured using enzymelinked fluorescence assay (VIDAS® BRAHMS PCT assay; Biomerieux, Lyon, France) according to the manufacturer's instructions while considering the limitation of this assay (0.05 ng/mL). Patients were divided into two groups; patients whose bronchoalveolar lavage (BAL) has shown the growth of more than 10 4 CFU/mL were included in confirmed VAP group and other patients were included in suspected VAP group.
The necessary patient information including age, gender, and length of stay in ICU, cause of hospitalization, duration of mechanical ventilation and time of VAP diagnosis were gathered. Serum and alveolar procalcitonin levels were measured and compared between both groups.
STATISTICAL ANALYSIS
The gathered data were analyzed using SPSS V.22 software. T-test and Chi-Square statistical methods were used for qualitative and quantitative variables. Moreover, receiver operating characteristic (ROC) curve analysis was used for optimal cutoff value. P < 0.05 was considered significant.
ETHICAL CONSIDERATION
The study protocol was approved by the ethics committee of Babol University of Medical Sciences.
RESULTS
Of 50 studied patients, 23 were male (46%) and 27 were female (54%) with mean age of 69.10 ± 42.13 and a range of 16-90 years. There were 26 patients (52%) with suspected VAP and 24 patients (48%) with confirmed VAP (Table 1 ). The mean length of stay in the intensive care unit was 9.74 ± 2.64 days. Moreover, patients' mean clinical pulmonary infection score was reported to be 7.02 ± 1.07.
Cutoff value for alveolar procalcitonin for the diagnosis of VAP (AUC = 0.683) was calculated to be 709.5 ng/mL (sensitivity = 57%; specificity = 80%) ( Figure 1) (Table 3) . Accordingly, the mean alveolar procalcitonin with a range of 271-957 ng/mL was calculated to be 607.80 ± 199.38 ng/mL. There was a significant difference between alveolar procalcitonin level in patients with suspected VAP and patients with confirmed VAP (p = 0.027) in a way that the mean alveolar procalcitonin was 551.00 ± 200.55 ng/mL in patients with suspected VAP and was 660.23 ± 186.97 ng/mL in patients with confirmed VAP (Table 2) . Cutoff value for serum procalcitonin for the diagnosis of VAP (AUC = 0.751) was calculated to be 0.45 ng/mL (sensitivity = 71%; specificity = 73%) ( Figure 1) (Table 3) . Accordingly, the mean serum procalcitonin level was 046 ± 0.06 ng/mL in patients with confirmed VAP and it was 0.38 ± 0.08 ng/mL in patients with suspected VAP and this difference was significant (p = 0.001) ( Table 2) .
Moreover, regarding categorization of clinical pulmonary infection score, patients with CPIS < 8 had a mean alveolar procalcitonin of 575.45 ± 184.79 ng/mL and patients with CPIS ≥ 8 had a mean alveolar procalcitonin of 652.48 ± 214.42 ng/mL and the difference was not statistically significant (p = 0.15). In addition, patients with CPIS <8 had a mean serum procalcitonin of 0.40 ± 0.08 ng/mL and patients with CPIS ≥ 8 had a mean serum procalcitonin of 0.44 ± 0.07 ng/mL and no significant difference was reported (p = 0.07).
Lung and heart diseases were respectively the most and the least common causes of hospitalization in ICU patients. Serum and alveolar procalcitonin level in patients with different causes of hospitallization is presented in Table 4 . No significant difference was observed between serum and alveolar procalcitonin level and causes of hospitalization in the ICU (p = 0.77 and 0.17, respectively). 
DISCUSSION
The present study demonstrated that serum and alveolar procalcitonin level in patients with confirmed VAP was more than patients with suspected VAP. However, there was no significant difference between serum and alveolar procalcitonin level and categorization of clinical pulmonary infection score. Moreover, there was no significant difference between serum and alveolar procalcitonin level and hospitalization in the ICU.
There are similar studies that show there is a significant relationship between serum procalcitonin level and infection and this relationship introduces PCT as a useful test for early detection of systemic infections [13] [14] [15] . As a result, major changes in serum procalcitonin concentration make it a useful marker for diagnosis and prognosis of bacterial infections. The study of Aalto et al. regarding serum procalcitonin level showed an increased serum procalcitonin level in patients with infection [16] . Jiao et al., showed that serum PCT may be used as diagnostic marker for VAP in patients following cardiac surgery [17] . Assicot et al. demonstrated the diagnostic value of alveolar procalcitonin regarding the intensity and course of inflammatory responses to bacterial and fungal infections for the first time [18] . Thereafter, several studies have shown the close association of serum and alveolar procalcitonin level and severe invasive bacterial infections and its decline after appropriate antibiotic treatment.
As stated earlier, mean serum and alveolar procalcitonin level in patients with confirmed VAP was more than in patients with suspected VAP. Therefore, the results of the present study indicate that alveolar procalcitonin can also play a key role for the diagnosis of VAP. Zhou et al. found that alveolar procalcitonin level has high sensitivity in regard with the diagnosis of VAP and we can use the changes in alveolar procalcitonin level for quick diagnosis of VAP in early stages [19] . Liao et al. have reported that measuring alveolar procalcitonin level is highly effective in early diagnosis of VAP [20] . Decline in alveolar procalcitonin level can be predictive of survival due to appropriate response to treatment.
In the study of Duflo et al. serum procalcitonin level in patients with confirmed VAP was significantly higher than in other patients. Although this study demonstrated that accumulation of serum procalcitonin can be useful for the diagnosis of VAP, alveolar procalcitonin level is not useful for the diagnosis of this type of pneumonia and is not a proper marker for predicting mortality [21] . Ramirez et al. found that serum procalcitonin level can be effective in differentiating non-infectious lung diseases from infectious ones and contribute to the diagnosis of VAP; however, no such positive result was found regarding alveolar procalcitonin [22] . Linssen et al. reported in their study that the diagnostic value of alveolar procalcitonin in the diagnosis of VAP is less than serum procalcitonin [23] . In addition, several studies have noted that alveolar procalcitonin is not an exclusive marker for the diagnosis of VAP, whereas serum procalcitonin benefits from this characteristic. Usefulness of alveolar procalcitonin in some studies and its uselessness in some other studies may be due to blind and random sampling of bronchoalveolar lavage from uninvolved parts of lung, which may not show a true level of alveolar procalcitonin. The theory stated in the study of Monton et al. may be another reason. In his research, Monton stated that the produced cytokine may not be divided into smaller components and thus accumulation of alveolar procalcitonin may not be observed, which is true in pulmonary infections [24] .
Cutoff value for serum procalcitonin was reported to be 0.45 ng/mL with sensitivity of 71% and specificity of 73% and AUC of 0.751 (favorable) and the same index for alveolar procalcitonin was reported to be 709.5 ng/mL with sensitivity of 57% and specificity of 80% and AUC of 0.683 (relatively favorable). Considering the relative equality of test properties, AUC and difference in their sensitivity, one may conclude that, although serum procalcitonin test can be used as a diagnostic method with relatively favorable and cost-effective properties for the diagnosis of VAP, measuring alveolar procalcitonin can also be considered as another useful method for early diagnosis of this infection due to specificity of samples (lung) as opposed to serum procalcitonin which may also increase in other organs.
Therefore, procalcitonin test is advised to be used for patients, whose diagnosis of bacterial infections, particularly VAP, is not certain and serum procalcitonin level should be measured at early stages of the disease and during treatment using this test. There were some limitations in this recent study. The number of subjects was small and hence a study on a larger number of individuals is required. Moreover, cellular and molecular investigations like evaluation of regulatory T-cells as a marker in some infections and gene expression of cytokines related to create infection (VAP) for future study is suggested [25] .
CONCLUSION
Our results can be suggested that measuring the procalcitonin level, particularly alveolar procalcitonin, in ICU patients can contribute to early diagnosis of ventilator-associated pneumonia. 
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